Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022048 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab in Treating Patients With Myelodysplastic Syndrome
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00022048: Completed Phase 1 study, sponsored by Stanford University.
NCT00022048 is a Phase 1 study that has completed, run by Stanford University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022048, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PURPOSE: This phase I/II trial is to see if bevacizumab works in treating patients who have myelodysplastic syndrome.
Interventions
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-08 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
What the finished NCT00022048 record still lists
NCT00022048 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which bevacizumab is the first listed.
NCT00022048 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00022048 about?
NCT00022048 is a clinical study titled "Bevacizumab in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PURPOSE: This phase I/II trial is to see if bevacizu...
What is the current status of trial NCT00022048?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-08. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00022048?
The interventions under investigation include: bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00022048?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia